Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

* Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for c...

2024-04-25 20:00 1630

Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-04-06 08:30 3080

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

* Promising clinical activities and efficacies during dose escalations for four lead global right...

2024-03-22 18:00 5843

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2024-03-20 20:30 2107

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2024-03-20 08:30 1562

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) a...

2024-03-06 08:30 1930

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2023-12-14 09:55 1646

Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will ev...

2023-12-11 08:30 1352

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. * X...

2023-12-06 17:00 1671

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 a...

2023-11-17 08:00 1830

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (a...

2023-11-08 08:30 1590

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-11-01 08:30 1250

Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting

SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-09-28 08:30 1665

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenici...

2023-09-21 18:05 1810

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2023-08-25 19:37 2096

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercializatio...

2023-08-11 08:00 2546

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusiv...

2023-07-18 08:30 2020

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has ...

2023-07-17 08:30 2389

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor...

2023-06-01 10:09 2964

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 mo...

2023-05-26 09:41 2815